Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy

In late December 2019, a novel strand of Coronavirus (SARS-CoV-2) causing a severe, potentially fatal respiratory syndrome (COVID-19) was identified in Wuhan, Hubei Province, China and is causing outbreaks in multiple world countries, soon becoming a pandemic. Italy has now become the most hit country outside of Asia: on March 16, 2020, the Italian Civil Protection documented a total of 27980 confirmed cases and 2158 deaths of people tested positive for SARS-CoV-2. In the context of an emerging infectious disease outbreak, it is of paramount importance to predict the trend of the epidemic in order to plan an effective control strategy and to determine its impact. This paper proposes a new epidemic model that discriminates between infected individuals depending on whether they have been diagnosed and on the severity of their symptoms. The distinction between diagnosed and non-diagnosed is important because non-diagnosed individuals are more likely to spread the infection than diagnosed ones, since the latter are typically isolated, and can explain misperceptions of the case fatality rate and of the seriousness of the epidemic phenomenon. Being able to predict the amount of patients that will develop life-threatening symptoms is important since the disease frequently requires hospitalisation (and even Intensive Care Unit admission) and challenges the healthcare system capacity. We show how the basic reproduction number can be redefined in the new framework, thus capturing the potential for epidemic containment. Simulation results are compared with real data on the COVID-19 epidemic in Italy, to show the validity of the model and compare different possible predicted scenarios depending on the adopted countermeasures.

[1]  Michael McAleer,et al.  Risk Management of COVID-19 by Universities in China , 2020, Journal of Risk and Financial Management.

[2]  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[3]  Shaoqiang Li,et al.  Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.

[4]  P. Klepac,et al.  Early dynamics of transmission and control of COVID-19: a mathematical modelling study , 2020, The Lancet Infectious Diseases.

[5]  L. Yang,et al.  Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, International Journal of Infectious Diseases.

[6]  P. Klepac,et al.  Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.

[7]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[8]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[9]  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[10]  W. O. Kermack,et al.  A contribution to the mathematical theory of epidemics , 1927 .

[11]  Francesco Casella Can the COVID-19 epidemic be managed on the basis of daily data? , 2020, ArXiv.

[12]  Yongli Cai,et al.  A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action , 2020, International Journal of Infectious Diseases.

[13]  M. E. Alexander,et al.  Modelling strategies for controlling SARS outbreaks , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[14]  Dan Xu,et al.  Positive RT-PCR Test Results in Patients Recovered From COVID-19. , 2020, JAMA.

[15]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[16]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[17]  Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking , 2020 .

[18]  Yuyi Wang,et al.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures , 2020, Journal of medical virology.

[19]  J. Hyman,et al.  Short-term Forecasts of the COVID-19 Epidemic in Guangdong and Zhejiang, China: February 13–23, 2020 , 2020, Journal of clinical medicine.

[20]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[21]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[22]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[23]  Frank Diederich,et al.  Mathematical Epidemiology Of Infectious Diseases Model Building Analysis And Interpretation , 2016 .

[24]  T. Velavan,et al.  The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.

[25]  Herbert W. Hethcote,et al.  The Mathematics of Infectious Diseases , 2000, SIAM Rev..

[26]  D. Cummings,et al.  Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions , 2020, medRxiv.

[27]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[28]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[29]  F. Brauer,et al.  Mathematical Models in Population Biology and Epidemiology , 2001 .

[30]  Maria Elena Bottazzi,et al.  The SARS-CoV-2 Vaccine Pipeline: an Overview , 2020, Current Tropical Medicine Reports.

[31]  Yunpeng Ji,et al.  Potential association between COVID-19 mortality and health-care resource availability , 2020, The Lancet Global Health.

[32]  G. Remuzzi,et al.  COVID-19 and Italy: what next? , 2020, The Lancet.

[33]  C. Anastassopoulou,et al.  Data-based analysis, modelling and forecasting of the COVID-19 outbreak , 2020, PloS one.

[34]  Maimuna S. Majumder,et al.  Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data , 2014, PLoS currents.

[35]  Per Block,et al.  Demographic science aids in understanding the spread and fatality rates of COVID-19 , 2020, Proceedings of the National Academy of Sciences.